GE Healthcare’s €132 Million Investment: Strengthening Ireland’s Biopharma Sector
Expansion Plan
GE Healthcare, a global leader in medical imaging and diagnostics, has announced a €132 million investment to expand its manufacturing facility in Carrigtwohill, County Cork, Ireland. This facility plays a crucial role in producing contrast agents, which are used in MRI and CT scans to enhance diagnostic accuracy.
The expansion will:
- Increase production capacity by 50%, allowing for an additional 25 million patient doses per year
- Create hundreds of new jobs in Ireland’s thriving life sciences industry
- Support the growing global demand for advanced medical imaging, driven by aging populations and the rise in chronic diseases like cancer and cardiovascular conditions
Ireland: A Global Biopharma Hub
Ireland has emerged as a leading destination for pharmaceutical and biotechnology investments, attracting major companies such as Pfizer, Johnson & Johnson, and Medtronic. With over 120 multinational life sciences firms operating in the country, the sector accounts for more than €80 billion in annual exports.
Economic and Industry Impact
- Job Creation: The expansion will provide high-skilled employment opportunities in engineering, research, and manufacturing.
- Innovation in Medical Imaging: GE Healthcare’s investment will support new developments in AI-assisted imaging and personalized diagnostics.
- Strengthening Ireland’s Position: Ireland is set to maintain its status as one of the world’s top biopharmaceutical manufacturing locations.
🔹 With continued investment in life sciences, Ireland is positioning itself as a key global player in the future of healthcare innovation.
